Investor Relations and Media
There are considerable unmet medical needs and therefore major commercial opportunities in both multiple sclerosis and other CNS diseases, currently with no efficient treatment. Subsequently, there are major additional potentials in ALS, Parkinson’s disease, depression and other CNS and autoimmune diseases.
There is established proof of concept in rodent disease models (mouse and rats) with potent results for treatment in MS, depression, Parkinson’s disease, and ALS. MIQ-001 has been tested in toxicology studies and in phase 1 clinical trials, with human volunteers with excellent results.